SCHEMBL787785

SCHEMBL787785

Nc1cc(C(=O)O)cc(C(F)(F)F)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 2/20 0.52
RXRA P19793 1/20 0.50
RXRB P28702 1/20 0.50
RXRG P48443 1/20 0.50
SRD5A2 P31213 2/20 0.46
KDM4E B2RXH2 2/20 0.46
ALDH1A1 P00352 2/20 0.46
HPGD P15428 1/20 0.46
HSD17B10 Q99714 1/20 0.46
AKR1C3 P42330 1/20 0.42
AKR1C2 P52895 1/20 0.42
MEN1 O00255 1/20 0.42
LMNA P02545 1/20 0.42
KMT2A Q03164 1/20 0.42
DDO Q99489 1/20 0.42
GAA P10253 1/20 0.42
DHODH Q02127 1/20 0.42
MRGPRX4 Q96LA9 2/20 0.41
TSHR P16473 1/20 0.41
MAPK1 P28482 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29451089 1.00 CES2 (0.52) CES2RXRARXRBRXRGSRD5A2
SCHEMBL7188717 0.86 CES2 (0.54) CES2RXRARXRBRXRGSRD5A2
SCHEMBL503980 0.85 CES2 (0.70) CES2RXRARXRBRXRGSRD5A2
SCHEMBL545011 0.85 CES2 (0.62) CES2RXRARXRBRXRGSRD5A2
SCHEMBL29523678 0.85 KDM4E (0.40) CES2RXRARXRBRXRGSRD5A2
SCHEMBL20591292 0.85 KDM4E (0.40) CES2RXRARXRBRXRGSRD5A2
SCHEMBL4472344 0.84 CES2 (0.52) CES2RXRARXRBRXRGKDM4E
SCHEMBL28119413 0.83 CES2 (0.67) CES2RXRARXRBRXRGSRD5A2
Hydrochloric Acid SCHEMBL7485970 0.83 CES2 (0.67) CES2RXRARXRBRXRGSRD5A2
SCHEMBL4974165 0.82 CES2 (0.50) CES2RXRARXRBRXRGAKR1C3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 325 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116162203-B High Tg cycloolefin copolymer and preparation method thereof 宁夏清研高分子新材料有限公司 2024-05-24 CN claimed
CN-113173864-B Graphene synergistic photo-thermal energy storage composite material and preparation method and application thereof 山西大同大学 2023-06-30 CN claimed
CN-116162203-A High Tg cycloolefin copolymer and preparation method thereof 宁夏清研高分子新材料有限公司 2023-05-26 CN claimed
CN-113173864-A Graphene synergistic photo-thermal energy storage composite material and preparation method and application thereof 山西大同大学 2021-07-27 CN claimed
WO-2018188785-A1 COMPOUND, COMPOUND FOR USE IN THE TREATMENT OF A PATHOLOGICAL CONDITION, A PHARMACEUTICAL COMPOSITION AND A METHOD FOR PREPARING SAID COMPOUND Technische Universität München (DE) 2018-10-18 WO claimed
EP-3388430-A1 COMPOUND, COMPOUND FOR USE IN THE TREATMENT OF A PATHOLOGICAL CONDITION, A PHARMACEUTICAL COMPOSITION AND A METHOD FOR PREPARING SAID COMPOUND Technische Universität München (DE) 2018-10-17 EP claimed
WO-2025137293-A2 ENHANCEMENT OF NUCLEIC ACID POLYMERIZATION BY AROMATIC COMPOUNDS Roche Sequencing Solutions, Inc. (US) 2025-06-26 WO disclosed
EP-4313293-B1 TETRAHYDROTHIENO PYRIDINE DERIVATIVES AS DDRS INHIBITORS CHIESI FARM SPA (IT) 2025-05-07 EP disclosed
EP-4267574-B1 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS AJAX THERAPEUTICS INC (US) 2025-04-23 EP disclosed
EP-4506349-A2 TETRAHYDROTHIENO PYRIDINE DERIVATIVES AS DDRS INHIBITORS Chiesi Farmaceutici S.p.A. (IT) 2025-02-12 EP disclosed
US-20240391936-A1 TETRAHYDROTHIENO PYRIDINE DERIVATIVES AS DDRS INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2024-11-28 US disclosed
US-12043632-B2 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors AJAX THERAPEUTICS, INC. (US) 2024-07-23 US disclosed
WO-2024130161-A2 NOVEL CAMPTOTHECIN DERIVATIVES AND CONJUGATES THEREOF BIONECURE THERAPEUTICS INC (US) 2024-06-20 WO disclosed
EP-0556674-B1 3,5-substituted benzoylguanidines with antiarrhythmic activity and cell proliferation inhibiting activity HOECHST AG (DE) 1996-06-19 EP disclosed
US-5516805-A 3,5-substituted aminobenzoylguanidines, their use as a medicament or diagnostic and medicament containing them HOECHST AKTIENGESELLSCHAFT (DE) 1996-05-14 US disclosed
US-5373024-A 3,5-Substituted benzoylguanidines, process for their preparation, their use as a medicament of diagnostic and medicament containing them HOECHST AKTIENGESELLSCHAFT (DE) 1994-12-13 US disclosed
EP-0612723-A1 Substituted benzoylguanidines, process for their preparation, their use as medicament, as inhibitor of the cellular Na+/H+ exchange or as diagnostic agent and medicament containing them HOECHST AKTIENGESELLSCHAFT (DE) 1994-08-31 EP disclosed
EP-0603650-A1 3,5-Substituted amino benzoylguanidines, process for their preparation, their use as medicine or diagnostic agent, as well as a medicine containing them HOECHST AKTIENGESELLSCHAFT (DE) 1994-06-29 EP disclosed
EP-0556674-A1 3,5-substituted benzoylguanidines with antiarrhythmic activity and cell proliferation inhibiting activity HOECHST AKTIENGESELLSCHAFT (DE) 1993-08-25 EP disclosed
US-3954994-A Intermediates for preparing hipolipemic agents and method of lowering the blood lipid level in mammals with said agents PFIZER INC. (US) 1976-05-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240391936-A1 TETRAHYDROTHIENO PYRIDINE DERIVATIVES AS DDRS INHIBITORS DDR1, DDR2, DDRGK1 CES2 4765/4885RXRA 1335/4885RXRB 888/4885
US-12043632-B2 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors JAK2, JAK3, STAT5B CES2 4082/4885RXRA 2930/4885RXRB 1871/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.